Optiscan CEO and Managing Director Camile Farah sat down with Stockhead’s Sarah Hughan where he discussed the company's agreement with Mayo Clinic.

During the interview Camile highlighted the growth within the multi billion dollar robotic assisted surgery market, and the impact Optiscan's collaboration with Mayo Clinic will have.

"Bringing the minimally invasive robotic surgery approach with our cutting edge, real-time, digital pathology platform really gives surgeons, hospitals and patients that ability to move through that patient care cycle with ease, minimal complications, less repeat surgery; which frees up operating theatres and doctors to do other procedures, and makes sure the patient doesn't have to go through more trauma for their care."

Watch the full interview here.